Adults with sickle cell disease are living far longer than they did a generation ago. According to a MedPage Today report, life expectancy in the 1970s was less than 20 years, with some estimates as low as 14. By 2022, half of patients who died were at least 60 years old, a decade older than in 2008. The shift reflects both new treatment options and a more active approach to managing the disease.
The approval of two gene therapies, exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia), offers a potential cure for patients who lack suitable bone marrow donors. However, uptake has been minimal: only about 165 people received the combined treatments in 2025, compared with roughly 100,000 Americans living with sickle cell disease. High list prices, intensive treatment requirements, and patient eligibility limits mean these therapies will likely change life for a subset of patients, not everyone.
Just as important, comprehensive care centers have improved routine management. Clinicians now screen for organ damage, check for sleep apnea, and incorporate non-opioid pain treatments and behavioral therapy. They also emphasize treating the underlying disease with hydroxyurea or transfusion rather than accepting chronic anemia as a stable baseline. The report notes that this level of care is not universal; patients at centers of excellence may receive better outcomes than those in community practices.
Evidence-based guidance is still evolving, with open questions about pregnancy care, mental health, and optimal pain management. Groups such as the National Alliance of Sickle Cell Centers are publishing consensus recommendations to fill those gaps. For now, the survival gains are real, even if access to advanced care and curative therapies remains uneven.